EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

INIFY Laboratories AB (INIFY) fair value: what the stock is really worth

We calculate from audited financials what INIFY Laboratories AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · NO

IL Thin data Sep 13, 2026

INIFY Laboratories AB

INIFY · OL

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 2.60 · Strongly overvalued (−55%)
!Quality 36/100
!Expensive Growth (revenue YoY +67.6 %/yr)
!negative free cash flow
!Trails peers (1/6)
!Narrow moat 40/100
!Insider activity 30/100
!Evidence only low, so the estimate is less certain
Watch INIFY Laboratories AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 16.20 kr 3.26 Fair Value kr 2.60 Jun 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

51‑month range kr 3.26 – kr 16.20 · fair‑value band kr 1.73 – kr 3.32 · the kr 5.80 price screens above the kr 2.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.

Stock analysis

INIFY Laboratories AB (INIFY) currently trades at kr 5.80, while our model-based Fair Value estimate is kr 2.60, implying the stock looks roughly 123.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 83/100, which puts the evidence level at low.

Scenario range: kr 1.73 (bear) to kr 3.32 (bull), the price of kr 5.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

INIFY Laboratories AB reported revenue of 22.0M SEK in FY2025 versus 1.2M SEK in FY2023, a compound +329.5%/yr. Reported net income was −67.9M SEK in FY2025.

Key figures

Market cap 849M NOK (≈ $91.4M) · EPS (TTM) kr −0.8900 · Return on equity −3,768% · Return on assets (EBIT) −77.7% · Free cash flow −105M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 90% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −55%, INIFY screens richer than that median.

Fair Value models

Bear kr 1.73 Fair Value kr 2.60 Bull kr 3.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.5000 kr 0.6600 kr 0.9900 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.5000 kr 0.6600 kr 0.9900 51

Open the full fair value analysis →

Notify me when INIFY reaches fair value

Put INIFY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 38 · Market factors (momentum, volatility) 37

Profitability 5
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 53
Price trend over the last 3–12 months (market factor)
52W Momentum 50
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

INIFY screens 123% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare INIFY Laboratories AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Profitability
Return on assets 0% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 0% · Below median
Growth and dividend
Revenue growth 0% · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.86× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $609.82 $616.38 +1%
Danaher Corporation DHR $200.14 $207.76 +4%
WuXi AppTec Co 2359 HK$188.80 HK$213.30 +13%
Lonza Group LONN CHF 531.20 CHF 151.69 −71%
IDEXX Laboratories, Inc IDXX $504.70 $511.54 +1%
Agilent Technologies, Inc A $146.93 $61.53 −58%
Waters Corporation WAT $408.34 $103.09 −75%
IQVIA Holdings IQV $261.77 $264.34 +1%
Illumina, Inc ILMN $206.45 $227.10 +10%
Mettler-Toledo International Inc MTD $1,294 $615.78 −52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

INIFY Laboratories AB · Fair Value
kr 2.60 −123%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "INIFY Laboratories AB Fair Value". https://www.fairvalue-calculator.com/stock/INIFY

Frequently asked questions

Is INIFY Laboratories AB (INIFY) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of kr 2.60 versus a price of kr 5.80, about −55% upside (overvalued).
What is the fair value of INIFY?
Our model-based fair value for INIFY Laboratories AB is kr 2.60 (as of Sep 13, 2026), built from audited fundamentals. The current price: kr 5.80.
What is the quality score of INIFY?
INIFY Laboratories AB has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INIFY Laboratories AB (INIFY)?
Our model-based price target is the fair value of kr 2.60 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario kr 1.73, optimistic scenario kr 3.32. It is a calculation from audited fundamentals, not an analyst target.
What is the INIFY Laboratories AB stock forecast for 2026?
Our models put fair value at kr 2.60, about −55% upside versus a price of kr 5.80 (overvalued). Cautious scenario kr 1.73, optimistic scenario kr 3.32. The calculation is refreshed regularly with new filings.
What is the intrinsic value of INIFY Laboratories AB (INIFY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INIFY Laboratories AB it is kr 2.60 per share (as of Sep 13, 2026), against a price of kr 5.80. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is INIFY Laboratories AB stock overvalued or undervalued in 2026?
As of Sep 13, 2026, INIFY trades above its calculated fair value: price kr 5.80, fair value kr 2.60, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INIFY?
No. The price is what the market pays today (kr 5.80); the fair value is what the company's own numbers justify (kr 2.60). For INIFY Laboratories AB the two are kr 3.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is INIFY Laboratories AB worth?
The market values INIFY Laboratories AB at about 849M NOK (market capitalisation, as of Sep 13, 2026). Per share that is kr 5.80; our models calculate a fair value of kr 2.60 per share.
What do the bullish and bearish scenarios say about INIFY?
Our models span a range for INIFY Laboratories AB: cautious scenario kr 1.73, base kr 2.60, optimistic kr 3.32 per share (as of Sep 13, 2026, price kr 5.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is INIFY from its 52-week high?
INIFY Laboratories AB trades at kr 5.80, about 16% below its 52-week high of kr 6.90 and 90% above the low of kr 3.06 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 2.60 is for.
Which stocks are comparable to INIFY Laboratories AB?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INIFY Laboratories AB stock attractive at the current price?
The data as of Sep 13, 2026: price kr 5.80, calculated fair value kr 2.60 (−55%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INIFY calculated?
We run INIFY Laboratories AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 2.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. INIFY Laboratories AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with INIFY Laboratories AB right now?
The price sits above even our optimistic bull case (kr 3.32). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 1.73 to kr 3.32) leaves room in how you read the outcome.

Key figures of INIFY Laboratories AB

How large is the market capitalisation of INIFY Laboratories AB (INIFY)?
The market capitalisation of INIFY Laboratories AB is 849M NOK (≈ $91.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of INIFY Laboratories AB (INIFY)?
Earnings per share at INIFY Laboratories AB are kr −0.8900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of INIFY Laboratories AB (INIFY)?
The return on equity (ROE) of INIFY Laboratories AB is −3,768% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INIFY Laboratories AB (INIFY)?
On an EBIT basis the return on assets of INIFY Laboratories AB is −77.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does INIFY Laboratories AB (INIFY) generate?
The free cash flow of INIFY Laboratories AB is −105M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch INIFY Laboratories AB in the live analysis

One click puts INIFY Laboratories AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.